OXT and Huntington disease: Furthermore, pretreatment with OXT before intracerebroventricular (icv) injection 3-nitropropionic acid (3-NP)-induced HD mouse model prevented the development of several changes including decreased levels of the OXT receptor, mGluR2 and glutathione as well as increased mGluR5 levels in the striatum, hippocampus, prefrontal cortex, and amygdala (Khodagholi et al., 2022).